China regulators may approve Beijing Brii Bio's COVID-19 dual antibody therapy under conditional use rules next month, according to a publication from the Ministry of Science and Technology. In October, Brii announced that the BRII-196/BRII-198 neutralizing mAb reduced hospitalizations and death by 78% in high-risk patients. The company also said the therapy was just as effective in days 6-10 after symptom onset as days 1-5, a surprising result. More details.... Stock  Symbol: (HK: 2137) Share this with colleagues: // //